Navinci announces stepping down of CEO, Robert Gunnarsson
Navinci announces CEO Robert Gunnarsson’s resignation, with Agata Zieba-Wicher as interim leader while the board searches for a permanent successor.
Navinci strengthens leadership with new Director of Operations
Navinci Diagnostics AB announces the appointment of Sopana Leife as new Director of Operations, effective September 2nd 2024.
Andrea Ballagi joins Navinci Board of Directors
Navinci are pleased to announce the appointment of Andrea Ballagi to the board, bringing further leadership expertise to the Company.
Leica Biosystems and Navinci Partner to Accelerate Cancer Research
Leica Biosystems, a global leader in anatomic pathology, and Navinci, announce a strategic collaboration to drive innovation in cancer patient care.
Navinci Presents Cutting-Edge Cancer Research at AACR24
Navinci will present our latest data on the annual meeting American Association for Cancer Research 2024 (AACR), in San Diego, US. Come by our booth and meet the team.
Product launch: Naveni® CD8/MHC-I kit
Introducing Naveni® CD8/MHC-I in situ assay kit, revealing immune response intricacies. Revolutionize cancer treatment with nuanced insights, advancing precision medicine.
Assay database alert! E-cadherin/β-catenin added
Explore our assay database’s new addition: E-cadherin/β-catenin interactions’ impact on cell adhesion and cancer progression, illuminating critical biological processes.
Exciting news: Explore our dynamic assay database!
Introducing our newest feature – the assay database, with demonstrated assays and protocols for targeted protein-protein interactions and specific protein detection!
Navinci Diagnostics has partnered with Shanghai Universal Biotech
Navinci Diagnostics has entered into a partnership with Shanghai Universal Biotech, becoming our exclusive distributor for the Chinese market.
Navinci and Research Instruments announce a strategic partnership
Navinci have reached a distribution partnership with leading supplier of cutting-edge research and life science tools Everlife-Research Instruments.
Exciting Times in the World of Proteomics!
Thermo Fisher Scientific’s remarkable $3.1 billion acquisition of Olink Proteomics is a testament to the incredible technology that forms the foundation of Olink Proteomics.
Expanding our reach – new distribution partnership in Italy
Navinci is excited to announce a distribution collaboration with EuroClone, a strategic move aimed at advancing our global sales expansion efforts.